A recently published Phase 3 trial demonstrated that adding atezolizumab to FOLFOX chemotherapyDrugs that kill rapidly dividing cells, including cancer cells.Click for full explanation → improved outcomes in Stage III dMMR colon cancer, and further Phase 3 work is evaluating atezolizumab added to combination chemotherapyDrugs that kill rapidly dividing cells, including cancer cells.Click for full explanation → or as a single agent in metastatic CRC.
ImmunotherapyTreatments that use the body's immune system to fight cancer.Click for full explanation → for the majority of CRC patients who do not have dMMR or MSI-H tumors remains an area of active investigation. Trials are combining checkpoint inhibitors with radiation, chemotherapyDrugs that kill rapidly dividing cells, including cancer cells.Click for full explanation →, and other immunotherapyTreatments that use the body's immune system to fight cancer.Click for full explanation → agents to find combinations that may activate immune responses in these harder-to-treat tumors.
Liquid biopsy using circulating tumor DNA (ctDNA) is being studied as a tool to detect minimal residual disease (MRD) after curative treatment. A Phase 2 trial is evaluating fruquintinib and tislelizumab specifically in patients with ctDNA-defined MRD after surgery, a precision medicine approach.
Cancer prevention is also under study. A Phase 2 trial is examining aspirin for prevention of colorectal cancer in patients with colorectal adenomas. A Phase 2 trial is testing a combination of vaccines for cancer prevention in Lynch syndrome, a hereditary predisposition to CRC.
Neoadjuvant regimens combining short-course radiotherapy with immunotherapyTreatments that use the body's immune system to fight cancer.Click for full explanation → including nivolumab or regorafenib are in Phase 2 for locally advanced rectal cancer.
Where the evidence stands
Adjuvant chemotherapyDrugs that kill rapidly dividing cells, including cancer cells.Click for full explanation → and metastatic regimens with bevacizumab or EGFR antibodies rest on strong Phase 3 evidence. Pembrolizumab for dMMR/MSI-H CRC has Phase 3 backing. ImmunotherapyTreatments that use the body's immune system to fight cancer.Click for full explanation → for non-MSI-H CRC remains an active problem, with Phase 2 and Phase 3 trials underway. BRAF-targeted combinations have Phase 3 support for a specific molecular subgroup. ctDNA-guided treatment, Lynch syndrome vaccines, and aspirin-based prevention are at Phase 2. AI-based colonoscopy assistance for polyp detection is an emerging research area.
What this means for people affected
Colorectal cancer treatment has benefited from targeted therapiesDrugs that block specific molecules that cancer cells need to grow.Click for full explanation → and immunotherapyTreatments that use the body's immune system to fight cancer.Click for full explanation → for molecularly defined subgroups. However, immunotherapyTreatments that use the body's immune system to fight cancer.Click for full explanation → is currently effective mainly for dMMR or MSI-H tumors, which represent roughly 15% of cases, and extending its benefit to the broader CRC population is a central research goal. Staging and molecular testing now play an important role in treatment planning, and early detection through screening remains a key tool in improving outcomes.
Last updated April 2, 2026
Recent research findings
Understanding evidence levels▼
PreclinicalLab or cell studies — no human data yet.
Animal StudyResults in animals only — may not apply to humans.
Phase 1 TrialFirst-in-human safety testing in small groups.
Phase 2 TrialEarly effectiveness testing in a larger group.
Phase 3 TrialLarge controlled trial — the strongest trial evidence.
Observational StudyPatterns observed in populations — not a controlled trial.
ReviewSummary analysis of multiple existing studies.
Meta-AnalysisStatistical pooling of results from multiple studies.
Observational StudyPatterns observed in populations over time, not a controlled experiment.Published: April 3, 2026
Cancer Mortality Trends in Young Adults Projected Through 2026
Researchers analyzed cancer deaths in 15 upper-middle and high-income countries to project mortality trends among young adults aged 25-49. They found that overall cancer mortality is expected to decline by 2026, but colorectal cancer mortality may increase in some countries.
Why it matters: This study provides insight into cancer mortality trends among young adults, which can inform future research and public health strategies.
Lab StudyLaboratory experiments on cells or tissue. No human or animal data.Published: April 3, 2026
UXT protein linked to colorectal cancer progression
Researchers studied the role of UXT protein in colorectal cancer. They found that UXT is associated with higher levels of a chemical called putrescine, which may contribute to cancer growth. Lab experiments showed that reducing UXT levels slowed cancer cell growth.
Why it matters: This finding may help scientists understand how colorectal cancer progresses and identify new targets for treatment.
The study was conducted in lab experiments and has not been tested in humans.
Phase 1 TrialFirst-in-human trial. Focuses on safety and dosing in small groups.Est. completion: November 30, 2027
Testing LDRT with Immunochemotherapy for Colorectal Cancer with Liver Metastasis
Researchers are studying the combination of low dose radiotherapy, short course radiotherapy, XELOX, and Tislelizumab for treating colorectal cancer that has spread to the liver. This trial is currently recruiting participants. The goal is to assess the safety and potential effectiveness of this treatment combination.
Why it matters: This trial may help doctors develop a more effective treatment plan for people with colorectal cancer that has spread to the liver.
ReviewSummary and analysis of existing published studies.Published: April 2, 2026
Lynch Syndrome Linked to Increased Risk of Upper Tract Urothelial Carcinoma
Researchers reviewed the connection between Lynch syndrome and upper tract urothelial carcinoma. They discussed molecular biology, diagnostic tools, and management options. The study highlighted the importance of considering Lynch syndrome in patients with upper tract urothelial carcinoma.
Why it matters: This finding may help clinicians identify patients at higher risk of developing upper tract urothelial carcinoma.
Observational StudyPatterns observed in populations over time, not a controlled experiment.Published: April 1, 2026
Rising Early-Onset Colorectal Cancer Rates: New Factors or Earlier Onset?
Researchers studied why early-onset colorectal cancer rates are increasing, especially among those under 45. They found that both new and known risk factors, such as obesity and poor diet, may play a role. More research is needed to understand these factors.
Why it matters: This finding highlights the need for further research to identify the causes of rising early-onset colorectal cancer rates.
Lab StudyLaboratory experiments on cells or tissue. No human or animal data.Published: April 1, 2026
Combining Stool and Blood Tests for Early Colorectal Cancer Detection
Researchers combined a stool test called FIT with a blood test that counts circulating tumor cells to see if it could help predict colorectal cancer. They found that this combination might be a useful tool for early detection, but more research is needed. The study suggests that this approach could be a new way to screen for colorectal cancer.
Why it matters: This finding could lead to a more accurate and noninvasive way to screen for colorectal cancer in the future.
✦ Significant findingA meaningful signal from later-stage research, or a strong phase 2 result that stands out from routine findings.Meta-AnalysisStatistical pooling of results from multiple studies.Published: April 1, 2026
AI-powered colonoscopy tools improve cancer detection rates
Researchers analyzed 48 studies involving 38,986 patients to compare the effectiveness of artificial intelligence-based computer-aided detection systems for colorectal polyps during colonoscopy. They found that several systems improved adenoma detection rates compared to standard colonoscopy without AI. However, the certainty of evidence varied and more research is needed.
Why it matters: This finding could lead to better detection and treatment of colorectal cancer in the future.
Efficacy
Several CADe systems improved adenoma detection rates, including ENDO-AID (risk ratio 1.26), CADEYE (risk ratio 1.18), and GI Genius (risk ratio 1.15).
Lab StudyLaboratory experiments on cells or tissue. No human or animal data.Published: April 1, 2026
AI Helps Accurately Identify Tumors in Rectal Cancer Images
Researchers used artificial intelligence to analyze MRI scans of rectal cancer patients. They found that their method could accurately identify tumors in over 70% of cases, with some improvements when using additional information about the rectum. However, the study's results are based on a relatively small group of patients.
Why it matters: This finding could help doctors more accurately diagnose and treat rectal cancer in the future.
Efficacy
Tumor segmentation DSC with the overlaid rectum was 75.52% (74.32-76.62)
Based on a total of 458 patients who underwent baseline rectal MR imaging.
Lab StudyLaboratory experiments on cells or tissue. No human or animal data.Published: April 1, 2026
Rising Colorectal Cancer in Young Adults May Be Linked to Childhood Exposure
Researchers looked at how early-life exposure to certain bacteria might contribute to colorectal cancer in people under 50. They suggest that this exposure could cause mutationsA change in DNA sequence that can drive cancer development.Click for full explanation → in the developing colon that lead to cancer years later. However, more research is needed to confirm this idea.
Why it matters: This finding could help us better understand why colorectal cancer is becoming more common in younger adults.
Lab StudyLaboratory experiments on cells or tissue. No human or animal data.Published: April 1, 2026
Challenging Precision in Colon Cancer Surgery
Researchers studied the hepatic flexure, a transition zone in the colon, and found that pre-operative localisation is challenging due to its non-discrete anatomy. They propose a new framework to better define this area. This may help tailor surgery to individual tumour biology and lymphatic drainage.
Why it matters: This finding may influence how surgeons plan and perform surgery, potentially leading to more targeted treatments for patients.
✦ Significant findingA meaningful signal from later-stage research, or a strong phase 2 result that stands out from routine findings.Meta-AnalysisStatistical pooling of results from multiple studies.Published: April 1, 2026
Aspirin's Effect on Colorectal Cancer Prevention Uncertain
Researchers reviewed 10 clinical trialsA research study that tests a medical intervention in human volunteers.Click for full explanation → involving over 124,000 people to see if aspirin prevents colorectal cancer. They found that aspirin may have little to no effect on colorectal cancer incidence in the first 15 years, but potential benefits and harms are uncertain. Aspirin may increase the risk of serious bleeding.
Why it matters: This finding highlights the complexity of using aspirin for colorectal cancer prevention and the need for individualized assessments.
The evidence is based on clinical trials, but the findings are uncertain and may be influenced by factors such as treatment contamination.
Observational StudyPatterns observed in populations over time, not a controlled experiment.Published: April 1, 2026
MRI Staging Accurate for Rectal Cancer
Researchers compared MRI staging of rectal cancer before surgery with the actual cancer stage after surgery. They found that MRI was accurate in staging the cancer's size and spread, but not always in identifying the number of cancer cells in the lymph nodes.
Why it matters: This finding could help doctors make better decisions about how to treat rectal cancer.
Testing the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresectable Colorectal Cancer That Have a BRAF MutationA change in DNA sequence that can drive cancer development.Click for full explanation →
Durvalumab and Tremelimumab With or Without High or Low-Dose Radiation Therapy in Treating Patients With Metastatic Colorectal or Non-small Cell Lung Cancer
Testing the Addition of Atezolizumab to Combination ChemotherapyDrugs that kill rapidly dividing cells, including cancer cells.Click for full explanation → or Atezolizumab Alone for Metastatic Colon or Rectal Cancer, the COMMIT Study
Testing the Addition of Anti-cancer Drug, ZEN003694, to the Usual ChemotherapyDrugs that kill rapidly dividing cells, including cancer cells.Click for full explanation → Treatment, Cetuximab Plus Encorafenib, for Colorectal Cancer
Testing the Addition of an Anti-Cancer Drug, ZEN003694, to the Usual ChemotherapyDrugs that kill rapidly dividing cells, including cancer cells.Click for full explanation → Treatment (Capecitabine) for Metastatic or Unresectable Cancers
A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer
